ABSTRACT
Hypermethylation of the gene regulatory regions are common for many cancer diseases. In this work we applied GLAD-PCR assay for identificating of the aberrantly methylated RCGY sites in the regulatory regions of some downregulated genes in tissue samples of lung cancer (LC). This list includes EFEMP1, EPHA5, HOXA5, HOXA9, LHX1, MYF6, NID2, OTX1, PAX9, RARB, RASSF1A, RXRG, SIX6, SKOR1 and TERT genes. The results of DNA samples from 40 cancer and 25 normal lung tissues showed a good diagnostic potential of selected RCGY sites in regulatory regions of MYF6, SIX6, RXRG, LHX1, RASSF1A and TERT genes with relatively high sensitivity (80.0 %) and specificity (88.0 %) of LC detection in tumor DNA.
Subject(s)
DNA Methylation , Lung Neoplasms/genetics , Polymerase Chain Reaction/methods , Regulatory Sequences, Nucleic Acid/genetics , Tumor Suppressor Proteins/genetics , HumansABSTRACT
The study of polymorphic variants of GSTT1, GSTM1 and GSTP1 genes from 61 patients with prostatic cancer (PC) has shown that incidence of 0/0 genotype GSTT1 and GSTM1 in PC patients was significantly higher of that in healthy men (n = 100) (34.4 and 15% in p = 0.007 and 60.7 and 43% in p = 0.04, respectively). PC risk in carriers of a GSTT1 deletion form was 2.97, CI95%--1.3-6.84, GSTM1--2.04 in CI95% 1.02-4.1. The analysis of combinations of pathological genotypes of xenobiotic biotransformation enzymes has demonstrated that 89.8% PC patients have a mutation in one of the genes GSTT1, GSTM1 or GSTP1.
Subject(s)
Glutathione S-Transferase pi/genetics , Glutathione Transferase/genetics , Mutation , Neoplasm Proteins/genetics , Polymorphism, Genetic , Prostatic Neoplasms/genetics , Aged , Aged, 80 and over , Genotype , Glutathione S-Transferase pi/metabolism , Glutathione Transferase/metabolism , Humans , Male , Middle Aged , Neoplasm Proteins/metabolism , Prostatic Neoplasms/enzymologyABSTRACT
Polymorphism of GSTT1 and GSTM1 variant genes of phase II biotransformation of xenobiotics was studied in 181 patients with lung cancer. Null genotype frequency in cancer patients was higher than in healthy subjects. It was still higher in metastatic cancer disseminated to the regional lymph nodes as compared with localized tumor.
Subject(s)
Biomarkers, Tumor/genetics , Glutathione Transferase/genetics , Lung Neoplasms/genetics , Polymorphism, Genetic , Aged , Case-Control Studies , Female , Genotype , Humans , Male , Middle AgedABSTRACT
A high single dose of radiation can be delivered precisely to tumor or regional metastasis area by means of intraoperative radiation therapy (IORT). A program of combined treatment including radical IORT, postoperative distant gamma-therapy and adjuvant polychemotherapy with cisplatin and etoposide has been developed at the Center. Treatment was given to 43 patients with stage III lung cancer. Complications were reported in 23.3 +/- 6.0%. Prophylactic methods have been worked out to minimize IORT--related postoperative complications. The postoperative lethality rate was 2.3 +/- 1.4%. No program-related hazards have been observed. Complications from adjuvant polychemotherapy were moderate.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Lung Neoplasms/therapy , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Chemotherapy, Adjuvant/adverse effects , Cisplatin/adverse effects , Etoposide/adverse effects , Female , Gamma Rays , Humans , Intraoperative Period , Lung Neoplasms/drug therapy , Lung Neoplasms/pathology , Lung Neoplasms/radiotherapy , Lung Neoplasms/surgery , Male , Middle Aged , Neoplasm Staging , Radiotherapy, Adjuvant/adverse effects , Radiotherapy, Adjuvant/methods , Treatment OutcomeABSTRACT
The results of 28 bronchoplastic operations for non-small cell lung cancer and 3-8 year follow-up have been evaluated. Intraoperative radiotherapy (IORT) (10 Gy) was conducted in 6 patients. IORT was used as a component of combined treatment with good results and without postoperative complications.
Subject(s)
Bronchial Neoplasms/radiotherapy , Bronchial Neoplasms/surgery , Carcinoma, Non-Small-Cell Lung/radiotherapy , Carcinoma, Non-Small-Cell Lung/surgery , Lung Neoplasms/radiotherapy , Lung Neoplasms/surgery , Adult , Follow-Up Studies , Humans , Intraoperative Period , Middle Aged , Radiotherapy/methods , Radiotherapy Dosage , Radiotherapy, Adjuvant , Treatment OutcomeABSTRACT
Autoantibody levels in patients with malignancies of the oral cavity and lung and autoimmune disorders have been assayed. It was found that tumors initiated polymorphous autoimmune reactions to various tissue antigens. Autoantibody production rates in tumor patients were comparable with those in autoimmune disorders. The role of autoimmune reactions in cancer pathogenesis is discussed.
